The molecular characterization of sporadic MTC at diagnosis, based on a search for somatic HRAS, KRAS, NRAS, or RET mutations, or miRNA expression profiling, will hopefully pave the way to a customized patient follow-up from the outset in the near future [3, 8]. The gene discussed is KRAS; the disease is medullary thyroid gland carcinoma.